Clinical Trials Logo

Clinical Trial Summary

114 patients between 18 and 50 years with an isolated focal cartilage defect in the knee will be randomized to either receive arthroscopic microfracture or arthroscopic debridement. Both groups will then undergo a systematic physiotherapy training regime for 6-9 months. The groups will then be compared for results, after 3, 6, 12 and 24 months, by using validated patient reported outcome scores (Lysholm, KOOS, Tegner) and EQ5D as well as clinical examination and radiological findings at 2 years (MRI).


Clinical Trial Description

Focal cartilage defects in the knee - A randomized controlled trial comparing arthroscopic microfracture with arthroscopic debridement. Clinical compare the effect of arthroscopic microfracture (MF) with arthroscopic debridement (AD) in patients with symptomatic full thickness knee cartilage injuries less than 2cm2. Focal cartilage injuries in the knee might have devastating effect both in the short term and in the long term. Various surgical treatment options are available, with microfracture the most used technique globally. Meta-analysis and systematic reviews have required well-designed, long-term, multicenter studies to evaluate clinical outcomes of microfracture with the use of a "no treatment" group as a control group. H0: There is no difference in KOOS QoL after AM or AD 24 months after surgery. H1: There is a difference in KOOS QoL after AM or AD 24 months after surgery. Questionnaires: KOOS, Tegner score, Lysholm score, EQ-5D, VAS. Physical examination: range of motion and hop test. Radiology: x-ray and MRI of the knee. Primary aim: KOOS quality of life (QoL) subscore. Prospective, double-blinded parallel-group multicenter study with 2 treatment arms. Approx. 24 months inclusion and 24 months follow up. In total 4 years. All will be invited to participate in late controls after 5 and 10 years. 6 Norwegian hospitals: Akershus University Hospital, Oslo University Hospital - Ullevaal, Kristiansund Hospital, Aalesund Hospital, Diakonhjemmet Hospital and Haukeland University Hospital. 114 patients Inclusion: age 18-50 years old, single symptomatic cartilage defect on femoral condyle or trochlea. 2 treatment groups with 57 patients in each group. Follow up after 3 months (± 2 weeks), 6 months (± 4 weeks), 12 months (± 6 weeks) and 24 months (± 8 weeks). All will be invited to participate in late controls after 5 and 10 years. If any unforeseen complication outside normal clinical practice occurs, the sponsor representative will be contacted as soon as possible with a parallel message to the local coordinators at the involved hospitals. During each follow up, there will be a case report form (CRF) regarding complications and safety. A 5 mL venous blood sample will be drawn on the day of operation. The blood sample will be centrifuged before serum is pipetted in a sterile tube. The serum will be analyzed at Oslo University Hospital - Rikshospitalet on the cartilage biomarker microRNA-140 (miR-140). If normal distribution, aims will be analyzed using linear mixed models (LMM), and the primary aim will be performed as a post hoc test for the LMM, similar to performing a two-sample t-test. If no normal distribution, analysis will be performed using Mann-Whitney U-test. Detecting a difference of 10 with 80 percent Power, uing a standard deviation of 18, this yields 52 patients in each group. By adding 10% due to loss during follow-up, we therefore plan to include a total of 114 patients. No interim analysis will be done. Monitor from Health Møre and Romsdal HF. The end of this study is 24 months after the last included patient. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02637505
Study type Interventional
Source University Hospital, Akershus
Contact
Status Completed
Phase N/A
Start date January 2016
Completion date September 28, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03479775 - Muscle Function and Traumatic Knee Injury in Sports
Recruiting NCT03321812 - Clinical Study of Decalcification Bone Scaffold for Cartilage Lesions of the Knee N/A
Recruiting NCT06082531 - Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis N/A
Completed NCT06078072 - Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
Completed NCT04889443 - Spontaneous Healing of ARticular Cartilage (SHARC)
Completed NCT04118023 - 7T MRI to Evaluate Cartilage Defects in the Knee
Active, not recruiting NCT01458782 - ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee N/A
Recruiting NCT03477942 - Impact of Mesenchymal Stem Cells in Knee Osteoarthritis Phase 1
Completed NCT01473199 - BioPoly RS Knee Registry Study for Cartilage Defect Replacement N/A
Recruiting NCT05124613 - The Impact of Covid-19 on Patients Waiting for Knee Surgery
Recruiting NCT06344481 - The Hyalex First-in-Human Study Phase 1
Completed NCT04739930 - Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation N/A
Active, not recruiting NCT03873545 - Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella
Recruiting NCT05328674 - Clinical and Comparative Evaluation of the Treatment Results of Arthroscopic Reconstruction of Cartilage Defects in the Knee Joint With the Use of Autogenous Cartilage Graft With PRP GF (Platelet-rich Plasma With Growth Factors) N/A
Recruiting NCT04184687 - The Treatment of Cartilaginous Lesions and Concomitant Anterior Cruciate Ligament Reconstruction N/A
Terminated NCT04301258 - ProChondrix® CR Articular Cartilage Restoration Evaluation (PACE) Registry
Completed NCT02696876 - Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair N/A
Recruiting NCT04135950 - Prospective Registry of Anterior Cruciate Ligament Reconstructions
Completed NCT03024801 - Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury N/A
Completed NCT01041001 - Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury Phase 3